Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 27, 2025
Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.
Journal: Nature communications
Published: April 01, 2025
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 03, 2025
RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
Journal: JCO precision oncology
Published: June 23, 2022
Trainee-Led Quality Improvement Project to Improve Fertility Preservation Counseling for Patients With Cancer.
Journal: JCO oncology practice
Published: September 27, 2021
Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.
Journal: Cancer letters
Published: June 24, 2020
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Journal: Thyroid : official journal of the American Thyroid Association
Published: June 16, 2020
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Journal: Cancer medicine
Published: September 06, 2019
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
Journal: Journal of oncology practice
Published: August 07, 2019
Single-board hematology fellowship track: a 10-year institutional experience.
Journal: Blood
Published: November 13, 2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Journal: Science (New York, N.Y.)
Published: May 17, 2017
Last Updated: 09/26/2026